Literature DB >> 24556355

Fabry disease: dose matters.

David G Warnock1, Michael Mauer.   

Abstract

Entities:  

Keywords:  chronic kidney disease; genetic renal disease; proteinuria

Mesh：

Substances：

Year:  2014        PMID： 24556355      PMCID： PMC3968510          DOI： 10.1681/ASN.2013121322

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN： 1046-6673            Impact factor:   10.121


× No keyword cloud information.
  22 in total

Review 1.  Enzyme replacement therapy for Fabry disease: lessons from two alpha-galactosidase A orphan products and one FDA approval.

Authors:  Robert J Desnick
Journal:  Expert Opin Biol Ther       Date:  2004-07       Impact factor: 4.388

2.  Safety and efficacy of recombinant human alpha-galactosidase A replacement therapy in Fabry's disease.

Authors:  C M Eng; N Guffon; W R Wilcox; D P Germain; P Lee; S Waldek; L Caplan; G E Linthorst; R J Desnick
Journal:  N Engl J Med       Date:  2001-07-05       Impact factor: 91.245

3.  Long-term therapy with agalsidase alfa for Fabry disease: safety and effects on renal function in a home infusion setting.

Authors:  Raphael Schiffmann; Markus Ries; Margaret Timmons; John T Flaherty; Roscoe O Brady
Journal:  Nephrol Dial Transplant       Date:  2005-10-04       Impact factor: 5.992

4.  Effects of switching from agalsidase Beta to agalsidase alfa in 10 patients with anderson-fabry disease.

Authors:  A Pisani; L Spinelli; B Visciano; I Capuano; M Sabbatini; E Riccio; G Messalli; M Imbriaco
Journal:  JIMD Rep       Date:  2012-10-21

5.  Prognostic indicators of renal disease progression in adults with Fabry disease: natural history data from the Fabry Registry.

Authors:  Christoph Wanner; João P Oliveira; Alberto Ortiz; Michael Mauer; Dominique P Germain; Gabor E Linthorst; Andreas L Serra; László Maródi; Renzo Mignani; Bruno Cianciaruso; Bojan Vujkovac; Roberta Lemay; Dana Beitner-Johnson; Stephen Waldek; David G Warnock
Journal:  Clin J Am Soc Nephrol       Date:  2010-09-02       Impact factor: 8.237

6.  Enzyme replacement therapy in Fabry disease: a randomized controlled trial.

Authors:  R Schiffmann; J B Kopp; H A Austin; S Sabnis; D F Moore; T Weibel; J E Balow; R O Brady
Journal:  JAMA       Date:  2001-06-06       Impact factor: 56.272

7.  Long-term enzyme replacement therapy is associated with reduced proteinuria and preserved proximal tubular function in women with Fabry disease.

Authors:  Thaneas Prabakaran; Henrik Birn; Bo M Bibby; Axel Regeniter; Søren S Sørensen; Ulla Feldt-Rasmussen; Rikke Nielsen; Erik I Christensen
Journal:  Nephrol Dial Transplant       Date:  2013-11-08       Impact factor: 5.992

8.  Patients with Fabry disease after enzyme replacement therapy dose reduction versus treatment switch.

Authors:  Frank Weidemann; Johannes Krämer; Thomas Duning; Malte Lenders; Sima Canaan-Kühl; Alice Krebs; Hans Guerrero González; Claudia Sommer; Nurcan Üçeyler; Markus Niemann; Stefan Störk; Michael Schelleckes; Stefanie Reiermann; Jörg Stypmann; Stefan-Martin Brand; Christoph Wanner; Eva Brand
Journal:  J Am Soc Nephrol       Date:  2014-02-20       Impact factor: 10.121

9.  Fabry disease: progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapy.

Authors:  Raphael Schiffmann; David G Warnock; Maryam Banikazemi; Jan Bultas; Gabor E Linthorst; Seymour Packman; Sven Asger Sorensen; William R Wilcox; Robert J Desnick
Journal:  Nephrol Dial Transplant       Date:  2009-02-13       Impact factor: 5.992

10.  Antiproteinuric therapy and fabry nephropathy: sustained reduction of proteinuria in patients receiving enzyme replacement therapy with agalsidase-beta.

Authors:  Hindia Tahir; Leslie L Jackson; David G Warnock
Journal:  J Am Soc Nephrol       Date:  2007-07-26       Impact factor: 10.121
View more
  12 in total

Review 1.  Nephrology research--the past, present and future.

Authors:  Jürgen Floege; Robert H Mak; Bruce A Molitoris; Giuseppe Remuzzi; Pierre Ronco
Journal:  Nat Rev Nephrol       Date:  2015-09-29       Impact factor: 28.314

2.  Serum-Mediated Inhibition of Enzyme Replacement Therapy in Fabry Disease.

Authors:  Malte Lenders; Jörg Stypmann; Thomas Duning; Boris Schmitz; Stefan-Martin Brand; Eva Brand
Journal:  J Am Soc Nephrol       Date:  2015-04-30       Impact factor: 10.121

3.  The Changing Landscape of Fabry Disease.

Authors:  Einar Svarstad; Hans Peter Marti
Journal:  Clin J Am Soc Nephrol       Date:  2020-03-04       Impact factor: 8.237

4.  Patients with Fabry Disease after Enzyme Replacement Therapy Dose Reduction and Switch-2-Year Follow-Up.

Authors:  Malte Lenders; Sima Canaan-Kühl; Johannes Krämer; Thomas Duning; Stefanie Reiermann; Claudia Sommer; Jörg Stypmann; Daniela Blaschke; Nurcan Üçeyler; Hans-Werner Hense; Stefan-Martin Brand; Christoph Wanner; Frank Weidemann; Eva Brand
Journal:  J Am Soc Nephrol       Date:  2015-07-16       Impact factor: 10.121

5.  Reduction of Plasma Globotriaosylsphingosine Levels After Switching from Agalsidase Alfa to Agalsidase Beta as Enzyme Replacement Therapy for Fabry Disease.

Authors:  Ozlem Goker-Alpan; Michael J Gambello; Gustavo H B Maegawa; Khan J Nedd; Daniel J Gruskin; Larry Blankstein; Neal J Weinreb
Journal:  JIMD Rep       Date:  2015-08-25

6.  Surges in proteinuria are associated with plasma GL-3 elevations in a young patient with classic Fabry disease.

Authors:  Takahiro Kanai; Takane Ito; Jun Odaka; Takashi Saito; Jun Aoyagi; Hiroyuki Betsui; Takanori Yamagata
Journal:  Eur J Pediatr       Date:  2015-10-10       Impact factor: 3.183

Review 7.  Progress in the understanding and treatment of Fabry disease.

Authors:  James J Miller; Adam J Kanack; Nancy M Dahms
Journal:  Biochim Biophys Acta Gen Subj       Date:  2019-09-14       Impact factor: 3.770

8.  Brazilian consensus recommendations for the diagnosis, screening, and treatment of individuals with fabry disease: Committee for Rare Diseases - Brazilian Society of Nephrology/2021.

Authors:  Cassiano Augusto Braga Silva; Luis Gustavo Modelli de Andrade; Maria Helena Vaisbich; Fellype de Carvalho Barreto
Journal:  J Bras Nefrol       Date:  2022 Apr-Jun

9.  Mosaicism of podocyte involvement is related to podocyte injury in females with Fabry disease.

Authors:  Michael Mauer; Emily Glynn; Einar Svarstad; Camilla Tøndel; Marie-Claire Gubler; Michael West; Alexey Sokolovskiy; Chester Whitley; Behzad Najafian
Journal:  PLoS One       Date:  2014-11-11       Impact factor: 3.240

10.  Agalsidase alfa and agalsidase beta in the treatment of Fabry disease: does the dose really matter?

Authors:  Antonio Pisani; Eleonora Riccio; Massimo Sabbatini
Journal:  Genet Med       Date:  2014-07-10       Impact factor: 8.822
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.